One clinical trial found reductions in the production of IL-13 and a decrease in the frequency of CD8+ T cells expressing TNF-α in the group of children with autism spectrum disorder (ASD) after they received treatment with BC products [87]. Here, CD8A is linked to autism spectrum disorder.